Navigation Links
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Date:1/12/2009

time. Investors interested in listening to the live webcast should log on before the presentation begins to download any software required. The archive of the presentation will be available for several days following the event.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is awaiting authorization to begin the delivery of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical development pipeline.

For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Call/--Hologic,Inc.(HologicortheCompany)(Nasdaq: H...remiumdiagnostics,medicalimagingsystemsandsurgical...n,isusingtheannualmeetingoftheRadiologicalSocietyo...ber29throughDecember3,2009tohighlightournewSecurVi...stationsoftware. ,, TheHologicSecurViewworkstat...
(Date:11/25/2009)...dsResearchGroup,Inc.releasedWave1ofits LaunchTren...yndicatedmarketresearchprojecttrackingthelaunchofC...oughthefirstsixmonthsofavailability.Eachwaveofther...rmatologistsandqualitativeinformationfromasubsetof...ouse,typicalpatienttypes,productperceptions,promot...
(Date:11/25/2009)...e/--AMPACFineChemicalsLLC(AFC),asubsidiaryofAmeric...hatitreceivedtheEnvironmentalResponsibilityandSust...mmit,sponsoredbytheCaliforniaManufacturersandTechn...ssociation(IEA)andtheChemicalIndustryCouncilofCali...sawardavailablefromallthreeorganizationsandgainssu...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 1AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 3AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 4AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 5AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 6AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 7AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 8AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 9AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 10AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 11AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 12AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 13AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 14AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 15AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 16AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 17AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 18AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 1AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 2AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 3First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 1First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 2First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 3
...reported in,the journal Pharmacogenomics suggests ...ic Factor gene (CNTF) may affect response to,antip...Pharmaceuticals,Inc., included patients with acute... with Fiapta(TM) (iloperidone), a novel atypical,a... FDA, or placebo.,Patients were also studied for a...
...r Blood-Derived Stem Cells and Strong In...NEW YORK, Feb. 28 NeoStem, Inc. (Amex: NBS ),whi...ssing and long-term,storage of adult stem cells fo...ositive research conclusions and industry trends p...sociation and at the recent Third Annual,Stem Cell...
Other Medicine Technology:Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 2NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 3NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 4
(Date:11/25/2009)...5/PRNewswire/--TheBartleHallConventionCenterwillte...c.9-10,whenKansasCityhoststhelatestinaseriesofmass...liniceventhasthepotentialtobethebiggestoneyet,beca...donweekdaysinsteadofoveraweekend,"SheriWood,execut...dentoftheNationalAssociationofFreeClinics(NAFC). ,...
(Date:11/25/2009)....25/PRNewswire-USNewswire/--AnarticlebyJanetWoodco...ndResearch,titled"ADifficultBalance-PainManagement...eofTheNewEnglandJournalofMedicine. ,, (Logo: ht... ) ,, Inthearticle,WoodcockdiscussesFDAeffortst...sewhoneeditandmanagingtherisksposedbyvariousanalge...
(Date:11/25/2009)...dence of a statistically significant survival bene...strogen receptor (ER)-positive tumors had high lev...(ER-alpha S118-P), according to a brief communicat...f the National Cancer Institute . , Approximatel...fen. Preclinical studies have shown that ER-alpha ...
(Date:11/25/2009)...aluation and treatment clinics to resume Monday, N...) November 25, 2009 -- Centegra Health System is c...ccine shots at four Centegra Primary Care (CPC) va...e has arrived. The clinics are at CPC sites in Hun... be open as follows: ,   From 4:30 to ...
(Date:11/25/2009).../PRNewswire-USNewswire/--TheAmericanAssociationfor...2009,"S.2128,whichisdesignedtosubstantiallyimprove....ThebillwasintroducedbySen.GeorgeLeMieux(R-Fla.). ...ericanAssociationforHomecareoutlinedinits13-pointa...ongressinFebruary.Thoseprovisionsincludecallingfor...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...RMD ),announced today that on Thursday, May 1, 200...ter of fiscal year 2008, ended March 31, 2008. Res...0 p.m. Pacific Time and will,host a conference cal...e webcast on ResMed,s website at http://www.resme...
...s E-Card, WHITE PLAINS, N.Y., April 17 This Moth...available free and exclusively,from the March of D...www.MomYouRock.com, can be,personalized by upload... positions -- star of the show.,She is the star of...
...n,s cognitive development , , THURSDAY, Ap... while on certain seizure medications do not appea...a new study finds. , "Our early findings show bre...r, of the University of Florida at Gainesville, sa...
...ng viruses, CDC says , , THURSDAY, April 1...has been the worst in four years, due, in part, to...irculating strains of flu virus, U.S. health offic...ut it was 100 percent ineffective against influenz...
...poration (Nasdaq: DYNT ) today announced the intr...ealth System for treating back pain and the,Dynatr...., "The new DynaPro Spinal Health System uses a f...dall,executive vice president of sales and marketi...
...t,Hospice, Inc., the nation,s 1st hospice, proudly... first class of The Norma F. Pfriem,International ...ed by a,generous grant merited by the Connecticut ...hip was established at,the Connecticut Hospice sta...
Other Medicine News:Health News:ResMed to Webcast Third Quarter 2008 Earnings Conference Call 2Health News:Mom You Rock! 2Health News:Breast-Feeding While on Seizure Meds Doesn't Harm Babies 2Health News:Current Flu Season Worst in 4 Years 2Health News:Current Flu Season Worst in 4 Years 3Health News:Dynatronics Introduces New DynaPro Spinal Health System and X5 'Turbo' 2Health News:The Norma F. Pfriem International Fellowship in Hospice and Palliative Care Nursing 2
Anti-MPO - ELISA (P-ANCA)
Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent Assay (ELISA)
Iso-Insulin ELISA
RIDASCREEN Anti-RSV IgM Assay
Medicine Products: